T-Cell Therapies offer enormous promise in the development of novel approaches to treating cancer. A federal appeals court recently heard arguments in a patent dispute between two companies that have emerged as leaders in CAR-T technology for new cancer treatments.
Juno Therapeutics in 2020 won a $1 billion judgment against Gilead’s Kite Pharma in connection with alleged infringement of U.S. Patent No. 7,446,190, entitled “Nucleic Acid Encoding Chimeric T Cell See more +
T-Cell Therapies offer enormous promise in the development of novel approaches to treating cancer. A federal appeals court recently heard arguments in a patent dispute between two companies that have emerged as leaders in CAR-T technology for new cancer treatments.
Juno Therapeutics in 2020 won a $1 billion judgment against Gilead’s Kite Pharma in connection with alleged infringement of U.S. Patent No. 7,446,190, entitled “Nucleic Acid Encoding Chimeric T Cell Receptors.”
The patent relates to a treatment approach that uses specially altered T cells — a part of the immune system — to fight cancer. The invention was developed at Sloan Kettering and licensed to Juno by a Sloan Kettering entity.
In this episode of the Harris Beach Podcast, partner Laura Smalley provides additional background, analyzes the Circuit Court arguments, and gives her thoughts on the implications of the case and what might happen next.
Laura is a member of our Intellectual Property Law Group, with a focus on areas such as patent infringement and litigation, pharmaceuticals, medical devices and life sciences, intellectual property protection and trademarks matters. See less -
